+91-8668442535

Small Animal Respiratory Diseases Treatment Market By Type Of Diseases (Allergic Pneumonitis, Canine Influenza, Canine Nasal Mites, Lung Nematodes, Neoplasia Of Respiratory System, Pneumonia, Rhinitis And Sinusitis, Tonsilitis), By Type Of Drug Class (Anthelmintics, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Antibiotics, Antihistamines, Phosphodiesterase (PDE) inhibitors, Bronchodilators, Antineoplastic Agents) - Growth, Future Prospects & Competitive Analysis, 2016 - 2024

This report on the global small animal respiratory diseases treatment market studies various types of diseases, drug classes, and geography. According to veterinary medical experts, upper respiratory infections, also called canine infectious respiratory disease (CIRD), are mainly caused in spaces occupied or visited by many pets, such as boarding houses, groomers, and parks.

These kinds of infections are also known commonly as "kennel cough" because of the honking, dry sound made by infected animals. URI in pets is complex to diagnose because it can be caused by both bacteria and viruses, and in most cases, multiple agents are involved. These infections are highly contagious, especially when dogs or cats get together in high-density situations such as pet stores and animal shelters. Sanitization is the most important factor.

For the purpose of this study, the various types of diseases considered are allergic pneumonitis, canine influenza, canine nasal mites, lung nematodes, neoplasia of the respiratory system, pneumonia, rhinitis and sinusitis, tonsillitis, and others. Market size estimates and forecasts for these segments for the period 2014–2024 are provided in terms of USD million, along with the respective CAGRs for the period 2016–2024, considering 2015 as the base year.

The market segmentation on the basis of types of drug class comprises sub-segments such as anthelmintics, NSAIDs, corticosteroids, antibiotics, antihistamines, phosphodiesterase (PDE) inhibitors, bronchodilators, antineoplastic agents, and others. Market size estimates and forecasts for these segments for the period 2014–2024 are provided in terms of USD million, along with the respective CAGRs for the period 2016–2024, considering 2015 as the base year.

The geographic segmentation of the global small animal respiratory diseases treatment market is performed for the regions of North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecasts for these segments for the period 2014–2024 are provided in terms of USD million, along with the respective CAGRs for the period 2016–2024, considering 2015 as the base year.

The key players covered in the small animal respiratory diseases treatment market are Zoetis, Inc., Merck Animal Health, Merial Inc. (Sanofi SA), Boehringer Ingelheim GmbH, Elanco Animal Health (Eli Lilly), Bayer AG, Ceva Animal Health Heska Corporation, Vetoquinol SA, Virbac Ltd., and Cipla Vet.

In May 2013, the Small Animal CPD Meeting sponsored by Boehringer Ingelheim Vetmedica involved discussion with experts about the common symptoms observed in small animals, such as coughing or dyspnea, and common disorders such as brachycephalic syndrome, laryngeal paralysis, tracheal collapse, and feline asthma syndrome.

Based on the type of respiratory diseases, the small animal respiratory disease treatment market is segmented into:

  • Allergic Pneumonitis
  • Canine Influenza
  • canine nasal mites
  • Lung Nematodes
  • Neoplasia of the Respiratory System
  • Pneumonia
  • Rhinitis and sinusitis
  • Tonsilitis
  • Others (Tracheobronchitis, Lung Flukes, Pulmonary Thromboembolism, and Feline Respiratory Disease Complex)

According to market experts, allergic pneumonitis, canine influenza, rhinitis, sinusitis, and tonsillitis were observed as the most common respiratory diseases observed in small animals. According to the American Veterinary Medical Foundation, the first recognized U.S. outbreak of H3N2 canine influenza occurred in 2015, starting in Chicago and spreading to other Midwestern states. Since March 2015, outbreaks have occurred in a number of areas throughout the U.S., and thousands of dogs have been confirmed positive for the H3N2 virus.

It was observed that the prevalence of canine influenza was also observed in cats, which displayed signs of upper respiratory disease, including discharge, congestion, malaise, lip smacking, and excessive salivation. Rhinitis and sinusitis are considered the most infrequent problems in small animals, but with changes occurring in the environment due to the presence of air pollution and sudden environmental change, this may lead to chronic nasal diseases.

The breed predilections for rhinitis and sinusitis comprise short-nosed, flat-faced cats that are more prone to chronic inflammation of the nose and, most of the time, fungal rhinitis. In the case of dogs, it is mainly observed in those with a long head and nose, and these dogs are more susceptible to Aspergillus infection and nasal tumors. According to a research paper published by Daniel L. Hamilos in ATS Journals, ambient mold spores are widely distributed in nature, and an estimated 3–10% of the world's animal population is allergic to molds. According to the study, there are compelling epidemiologic links between mold (fungal) allergy and illnesses such as asthma and asthma with allergic rhinitis.

Fungal allergies are more common in areas with high ambient mold spore concentrations. As a result, the developing pet-keeping trend in urban populations, which primarily involves small animals, affects the market dynamics of small animal respiratory disease treatment. Rising air pollution and abrupt environmental changes are affecting the respiratory health of small animals, and the maintenance of unsanitary conditions around pets also affects their respiratory systems.

According to the Royal Veterinary College, in the U.K., per 1000 dogs, 23.2 dogs suffering from Kennel Cough, 9.5 dogs suffer from coughing, 6.7 dogs are diagnosed with an upper respiratory tract infection (URTI), and 3.9 dogs suffer from brachycephalic airway obstruction syndrome (BAOS).

Based on the type of drug class, the small animal respiratory diseases treatment market is segmented into:

  • Anthelmintics
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Corticosteroids
  • Antibiotics
  • Antihistamines
  • Phosphodiesterase (PDE) inhibitors
  • Bronchodilators
  • Antineoplastic Agents
  • Others (beta-adrenergic receptor antagonists, anticoagulants, antitussives, and immunosuppressants)

In 2015, it was observed that anthelmintics, corticosteroids, and antibiotics accounted for more than 50% of the overall small animal respiratory diseases treatment market. According to market experts, most anthelmintics have wide safety margins, i.e., the dosage that can be given to an animal before adverse effects are induced is much higher than the dosage recommended for use. Thus, anthelmintics are prescribed with extreme caution in small animals, as the dose is critical in the treatment of diseases and the anticipated side effects.

The most commonly used antibiotics in small animal respiratory disease treatment are amoxicillin and cephalexin, sulfamethox, gentamicin, chloramphenicol, sulfadimethoxine, tetracycline, and doxycycline. The bacteria's growth and further multiplication are inhibited by bacteriostatic antibiotics. Glucocorticoids, through several mechanisms, project anti-inflammatory and immunosuppressive actions in the body that help overcome respiratory diseases in small animals.

For the purpose of this study, the global small animal respiratory diseases treatment market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

North America was observed as the largest market for small animal respiratory diseases treatment due to factors such as rising air pollution, lack of sanitation related to pets in a few households, the increasing urban trend of having dogs and cats as pets, and rising awareness associated with the well-being of small animals. The European small animal respiratory diseases treatment market has displayed significant growth recently, albeit from a fairly low base compared to other regions. According to market experts, consumers in the region are more likely to own pets and provide them with all the same facilities as a family member.

There is a noticeable inclination towards pet humanization, especially among young, urban, and affluent consumers, and they are expected to trade up to mid-priced or premium products. In 2015, Asia-Pacific was observed as the fastest-growing small animal respiratory diseases treatment market due to key driving factors such as the rising trend of keeping dogs and cats as pets in urban areas, increasing awareness in pet owners, especially associated with several life-threatening diseases, and the trend of pet humanization, which is increasing rapidly in Asian countries.

Frequently Asked Questions:

The market for Small Animal Respiratory Diseases Treatment Market is expected to reach USD 23,064.0 Mn By 2024.

The Small Animal Respiratory Diseases Treatment Market is expected to see significant CAGR growth over the coming years, at 2.5%.

The report is forecasted from 2016-2024.

The base year of this report is 2015.

Zoetis, Inc., Merck Animal Health, Merial Inc. (Sanofi SA), Boehringer Ingelheim GmbH, Elanco Animal Health (Eli Lilly), Bayer AG, Ceva Animal Health Heska Corporation, Vetoquinol SA, Virbac Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jan 2017
Category:  Pharmaceuticals
Report ID:   58332
Report Format:   PDF
Pages:   120
Rating:    4.5 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support